This is an aggregated industry headline. Read the full story at FierceBiotech →
AstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPC
AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug candidates.
By FierceBiotech
· Jul 4, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Nominate up-and-coming early-career pharma marketing pros here to be featured in Fierce's "Rising Stars" Q&…
The WeekBriefing
The FDA posted an updated list of all approved ANDAs with Competitive Generic Therapy designation, including e…
The WeekFiercePharma ↗
The ad uses hand-crafted puppets to portray sight-based frustrations for those with presbyopia, a common condi…